Seer, Inc.

NASDAQ:SEER

Biotechnology

Healthcare
$1.44 +0.29%

+$0.01 today

Market cap
$80.37M
Beta
1.59
P/E (TTM)
-1.4
EPS (TTM)
-$1.26
52W Low $1.65High $2.41

Volume 0.23M

Average 0.32M

SEER Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Seer, Inc.NASDAQ: SEER

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit dips below year-ago levels

Q1 FY2026 gross profit of $982K fell 52.4% year over year, behind the +61.1% change in trailing-twelve-month gross profit. Sequentially, it fell 52.2% from the prior quarter. Over 3 fiscal years it compounded at +70.5% a year.

Context

  • Gross profit amounted to 11.8% of revenue in FY2025, down 37.2 pp from a year earlier.
  • Gross profit increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -52.4% toward the trailing-twelve-month pace of +61.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$982K-52.2% QoQ
Last fiscal yearDec 2025
$1.9M-72.2% YoY
LTMMar 2026
$7.26M+61.1% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-52.4%——
1 year-72.2%——
3-year CAGR+70.5%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
1.9M USD
Year-over-year change
-72.2%

Gross Profit vs competitors

How SEER compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +61.1% is the 5th highest of 15, against a peer median of -7.5%.
  • Gross profit amounts to 48.3% of revenue for SEER, versus a peer median of 86.5%.
SEER Competitors
Gross Profit for SEER and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$607.18M USD+545.5%—86.5%
KYMRKymera Therapeutics, Inc.LTM Jun 2026$107.07M USD+151.2%-5.8%102.0%
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$40.92M USD-74.0%—95.3%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$33.06M USD-2.5%-3.5%94.8%
SEERSeer, Inc.LTM Mar 2026$7.26M USD+61.1%+70.5%48.3%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$6.28M USD-73.3%+12.8%22.3%
QSIQuantum-Si incorporatedLTM Mar 2026$741K USD-59.2%—40.0%
MNOVMediciNova, Inc.LTM Mar 2026$90.68K USD+1851.6%—15.2%
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$0 USD———
MLYSMineralys Therapeutics, Inc.LTM Jun 2026-$21K USD———
CGEMCullinan Therapeutics, Inc.LTM Mar 2026-$79K USD-2.6%——
PHVSPharvaris N.V.LTM Sep 2026-€106.45K EUR-9.7%——
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026-$320K USD-5.3%——
STTKShattuck Labs, Inc.LTM Mar 2026-$820K USD-146.7%—82.0%
PEPGPepGen Inc.LTM Mar 2026-$1.72M USD-351.6%——
LYELLyell Immunopharma, Inc.LTM Mar 2026-$2.3M USD-3640.0%—7422.6%
NKTXNkarta, Inc.LTM Mar 2026-$2.34M USD———
SANASana Biotechnology, Inc.LTM Mar 2026-$2.39M USD———
MOLNMolecular Partners AGLTM Mar 2026-CHF 2.61M CHF+91.8%——
Peer median (excluding SEER) —-7.5%-3.5%86.5%

Competitors are the stored peer set for SEER. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.39M14.69M15.18M13.95M16.12M
Cost of Revenue6.77M14.3M13.73M7.12M14.22M
Gross Profit(374K)384K1.45M6.83M1.9M
Gross Margin-5.8%2.6%9.5%49.0%11.8%
Research & Development29.12M45.8M47.44M50.59M37.77M
Selling, General & Admin42.2M52.63M58.95M56.57M42.58M
Operating Expenses71.32M98.43M106.39M106.93M80.35M
Depreciation & Amortization3.56M5.9M5.58M6.18M6.1M
EBITDA(67.61M)(87.07M)(80.7M)(80.33M)(67.3M)
EBITDA Margin-1057.3%-592.9%-531.5%-575.9%-417.5%
Operating Income(71.7M)(98.04M)(104.94M)(100.1M)(78.45M)
Operating Margin-1121.3%-667.6%-691.2%-717.7%-486.7%
Interest Income326K4.6M17.76M16.67M11.52M
Interest Expense22K0000
Other Income / Expenses527K5.08M18.67M13.6M5.05M
Income Before Tax(71.17M)(92.97M)(86.28M)(86.5M)(73.4M)
Pre-Tax Margin-1113.1%-633.1%-568.3%-620.2%-455.4%
Income Tax Expense00098K201K
Net Income(71.17M)(92.97M)(86.28M)(86.6M)(73.6M)
Net Margin-1113.1%-633.1%-568.3%-620.9%-456.6%
EPS (Basic)(1.13)(1.42)(1.35)(1.39)(1.28)
EPS (Diluted)(1.13)(1.42)(1.35)(1.39)(1.28)
Weighted Avg Shares60.86M62.43M63.85M62.35M57.45M
Weighted Avg Shares (Diluted)60.86M62.43M63.85M62.35M57.45M

Seer, Inc.

NASDAQ:SEER

Intrinsic Alpha fair value

Locked

Current Price

$1.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.